Pediatric acute epiglottitis and supraglottitis

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Survivors of pediatric ALL treated with contemporary chemotherapy performed significantly below normative population means on measures of executive functioning, verbal short-term memory, visual sustai

Effect: decline; mean = 8.05 (NEPSY-II Response Set); CI: 95% CI: 6.60-9.49

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%

Pediatric APL patients with FLT3 mutations had a dramatically higher rate of high diagnostic WBC count (>10,000 cells/uL) at 70% compared to 26% in FLT3 wild-type patients, with median WBC of 32,950 v

Effect: decline; 70% vs 26%